ArticleDiscover oncology2025
microRNA-1258 suppresses breast cancer progression by targeting LARP4B.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is the most common cancer in women. The majority of BC-related deaths result from metastasis and invasion. MicroRNA (miRNA) is a key regulatory factor that suppresses the expression of target genes. miR-1258 is considered one of the miRNAs significantly associated with BC, but its downstream target genes have not been fully defined. Our study aimed to elucidate the role of miR-1258 in breast cancer cell proliferation, migration, and invasion, identify its potential targets, and investigate its regulatory mechanisms.
methodsmiR-1258 expression in breast cancer was measured by Real‑time quantitative PCR. The effects of the Cell Counting Kit-8 method, the Transwell migration and invasion method on the behavior of tumor-related cells were studied. In addition, the interaction between miR-1258 and LARP4B in cancer was elucidated using dual-luciferase assays and Pearson correlation analysis.
resultsmiR-1258 is significantly downregulated in breast cancer, whereas LARP4B is significantly upregulated; both are closely associated with patients’ TNM staging. miR-1258 is an independent prognostic factor; patients with low expression of miR-1258 exhibit shorter overall survival. In BC cells, overexpression of miR-1258 inhibits cell proliferation, migration, and invasion. LARP4B is a potential target gene of miR-1258, and silencing LARP4B inhibits cellular biological functions.
conclusionsLow expression of miR-1258 may indicate poor prognosis in BC whilst its overexpression significantly inhibits proliferation, migration and invasion of BC cells. miR-1258 may inhibit BC progression by negatively regulating LARP4B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.